Gregory Russotti
Chief Tech/Sci/R&D Officer presso CENTURY THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and the Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. He previously worked at Celgene Corp.
as the VP of Cell Therapy Development and Operations from 2013 to 2019.
Dr. Russotti holds a doctorate degree from Rutgers State University of New Jersey, as well as undergraduate and graduate degrees from Rensselaer Polytechnic Institute.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 06/05/2024 | 385 092 ( 0.48% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Gregory Russotti
| Società | Posizione | Inizio |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
Dynamk Capital LLC
 Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Consultant / Advisor | - |
Precedenti posizioni note di Gregory Russotti
| Società | Posizione | Fine |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 31/12/2019 |
Formazione di Gregory Russotti
| Rutgers State University of New Jersey | Doctorate Degree |
| Rensselaer Polytechnic Institute | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Finance |
- Borsa valori
- Insiders
- Gregory Russotti
